727 related articles for article (PubMed ID: 29266249)
41. Muscle-specific kinase myasthenia gravis IgG4 autoantibodies cause severe neuromuscular junction dysfunction in mice.
Klooster R; Plomp JJ; Huijbers MG; Niks EH; Straasheijm KR; Detmers FJ; Hermans PW; Sleijpen K; Verrips A; Losen M; Martinez-Martinez P; De Baets MH; van der Maarel SM; Verschuuren JJ
Brain; 2012 Apr; 135(Pt 4):1081-101. PubMed ID: 22396395
[TBL] [Abstract][Full Text] [Related]
42. Nature and Action of Antibodies in Myasthenia Gravis.
Ruff RL; Lisak RP
Neurol Clin; 2018 May; 36(2):275-291. PubMed ID: 29655450
[TBL] [Abstract][Full Text] [Related]
43. Receptor clustering and pathogenic complement activation in myasthenia gravis depend on synergy between antibodies with multiple subunit specificities.
Rose N; Holdermann S; Callegari I; Kim H; Fruh I; Kappos L; Kuhle J; Müller M; Sanderson NSR; Derfuss T
Acta Neuropathol; 2022 Nov; 144(5):1005-1025. PubMed ID: 36074148
[TBL] [Abstract][Full Text] [Related]
44. Using Xenopus tissue cultures for the study of myasthenia gravis pathogenesis.
Yeo HL; Lim JY; Fukami Y; Yuki N; Lee CW
Dev Biol; 2015 Dec; 408(2):244-51. PubMed ID: 25746216
[TBL] [Abstract][Full Text] [Related]
45. Mechanisms of acetylcholine receptor loss in myasthenia gravis.
Drachman DB; Adams RN; Stanley EF; Pestronk A
J Neurol Neurosurg Psychiatry; 1980 Jul; 43(7):601-10. PubMed ID: 6249894
[TBL] [Abstract][Full Text] [Related]
46. Activation of the classical complement pathway in myasthenia gravis with acetylcholine receptor antibodies.
Ozawa Y; Uzawa A; Onishi Y; Yasuda M; Kojima Y; Kuwabara S
Muscle Nerve; 2023 Nov; 68(5):798-804. PubMed ID: 37705312
[TBL] [Abstract][Full Text] [Related]
47. DAF/CD55 and Protectin/CD59 modulate adaptive immunity and disease outcome in experimental autoimmune myasthenia gravis.
Soltys J; Halperin JA; Xuebin Q
J Neuroimmunol; 2012 Mar; 244(1-2):63-9. PubMed ID: 22325826
[TBL] [Abstract][Full Text] [Related]
48. Autoimmune myasthenia gravis: autoantibody mechanisms and new developments on immune regulation.
Le Panse R; Berrih-Aknin S
Curr Opin Neurol; 2013 Oct; 26(5):569-76. PubMed ID: 23995274
[TBL] [Abstract][Full Text] [Related]
49. Induction of Anti-agrin Antibodies Causes Myasthenia Gravis in Mice.
Yan M; Liu Z; Fei E; Chen W; Lai X; Luo B; Chen P; Jing H; Pan JX; Rivner MH; Xiong WC; Mei L
Neuroscience; 2018 Mar; 373():113-121. PubMed ID: 29339325
[TBL] [Abstract][Full Text] [Related]
50. Complement membrane attack is required for endplate damage and clinical disease in passive experimental myasthenia gravis in Lewis rats.
Chamberlain-Banoub J; Neal JW; Mizuno M; Harris CL; Morgan BP
Clin Exp Immunol; 2006 Nov; 146(2):278-86. PubMed ID: 17034580
[TBL] [Abstract][Full Text] [Related]
51. [Pseudo-internuclear ophthalmoplegia in myasthenia gravis].
Bogdan I; Crisanda V
Oftalmologia; 2011; 55(3):70-3. PubMed ID: 22428294
[TBL] [Abstract][Full Text] [Related]
52. Exogenous IL-9 Ameliorates Experimental Autoimmune Myasthenia Gravis Symptoms in Rats.
Yao X; Zhao J; Kong Q; Xie X; Wang J; Sun B; Xu L; Mu L; Li H
Immunol Invest; 2018 Oct; 47(7):712-724. PubMed ID: 29944018
[TBL] [Abstract][Full Text] [Related]
53. Eculizumab for the treatment of myasthenia gravis.
Mantegazza R; Cavalcante P
Expert Opin Biol Ther; 2020 Sep; 20(9):991-998. PubMed ID: 32602752
[TBL] [Abstract][Full Text] [Related]
54. Predictive value of serum anti-C1q antibody levels in experimental autoimmune myasthenia gravis.
Tüzün E; Saini SS; Ghosh S; Rowin J; Meriggioli MN; Christadoss P
Neuromuscul Disord; 2006 Feb; 16(2):137-43. PubMed ID: 16427283
[TBL] [Abstract][Full Text] [Related]
55. The role of complement in experimental autoimmune myasthenia gravis.
Kusner LL; Kaminski HJ
Ann N Y Acad Sci; 2012 Dec; 1274(1):127-32. PubMed ID: 23252907
[TBL] [Abstract][Full Text] [Related]
56. [Autoantibodies in myasthenia gravis].
Motomura M; Narita Masuda T
Brain Nerve; 2013 Apr; 65(4):433-9. PubMed ID: 23568991
[TBL] [Abstract][Full Text] [Related]
57. [Myasthenia gravis induced by autoantibodies against MuSK].
Shigemoto K; Konishi T; Ohta M
Nihon Rinsho; 2008 Jun; 66(6):1149-54. PubMed ID: 18540361
[TBL] [Abstract][Full Text] [Related]
58. Pathophysiology of myasthenia gravis.
Hughes BW; Moro De Casillas ML; Kaminski HJ
Semin Neurol; 2004 Mar; 24(1):21-30. PubMed ID: 15229789
[TBL] [Abstract][Full Text] [Related]
59. Autoimmune Attack of the Neuromuscular Junction in Myasthenia Gravis: Nicotinic Acetylcholine Receptors and Other Targets.
Paz ML; Barrantes FJ
ACS Chem Neurosci; 2019 May; 10(5):2186-2194. PubMed ID: 30916550
[TBL] [Abstract][Full Text] [Related]
60. A randomized, double-blind, placebo-controlled phase II study of eculizumab in patients with refractory generalized myasthenia gravis.
Howard JF; Barohn RJ; Cutter GR; Freimer M; Juel VC; Mozaffar T; Mellion ML; Benatar MG; Farrugia ME; Wang JJ; Malhotra SS; Kissel JT;
Muscle Nerve; 2013 Jul; 48(1):76-84. PubMed ID: 23512355
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
